Developer docs
API playgroundTry for free, no card

Search company profiles

Augustine Therapeutics

Full company profile

uuid0000lrv

Namestring
Augustine Therapeutics
Legal namestring
Augustine Therapeutics NV
Websiteurl
augustinetx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Augustine Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 as a spin-off from VIB and KU Leuven, headquartered in Leuven, Belgium with a wholly-owned Copenhagen research subsidiary (Augustine Therapeutics Denmark ApS) established in May 2025. The company develops a portfolio of next-generation selective HDAC6 inhibitors built on a proprietary non-hydroxamate, non-hydrazide producing chemotype designed to overcome the specificity limitations, off-target toxicity, and poor drug-like properties of first-generation hydroxamate- and oxadiazole-based HDAC6 inhibitors. Its pipeline targets three therapeutic verticals with high unmet need: neuromuscular diseases led by AGT-100216 in Phase I clinical trials for Charcot-Marie-Tooth disease (a hereditary neuropathy affecting more than 2.5 million people worldwide with no approved disease-modifying treatments); neurodegenerative diseases via brain-penetrant HDAC6 candidates in lead optimization for ALS and other CNS indications; and cardio-metabolic diseases via a second-generation peripherally-restricted program in advanced lead optimization for conditions including heart failure with preserved ejection fraction and atrial fibrillation.

The company's technology platform is grounded in research from Prof. Ludo Van Den Bosch at the VIB-KU Leuven Center for Brain & Disease Research and includes both peripherally-restricted and brain-penetrant selective HDAC6 chemotypes protected by pending patent filings on thiomethyl carbonyl HDAC6/HDAC1/HDAC3 inhibitors. Augustine has built a senior leadership team with extensive big-pharma and biotech experience across Sanofi, Pfizer, Lundbeck, Genzyme, AbbVie, AstraZeneca, Zealand Pharma, and Arkuda Therapeutics, and has constructed a multi-asset pipeline spanning IND-enabling, lead optimization, and clinical stages.

The business model is a traditional pharmaceutical development and commercialization path: Augustine is pre-revenue with no approved products and no disclosed pricing, plans to commercialize through standard pharmaceutical distribution (prescribing physicians, hospital and specialty pharmacies) upon regulatory approval, and acknowledges potential future partnerships with larger pharmaceutical companies for global commercialization. Current funding is sourced from venture capital (cumulative Series A funding of approximately EUR 94.7M led by Novo Holdings, Jeito Capital, Asabys Partners, and Eli Lilly) plus non-dilutive grants from the US ALS Association and the Flanders Agency for Innovation and Entrepreneurship (VLAIO).

Short descriptiontext

Augustine Therapeutics is a clinical-stage Belgian biopharmaceutical company developing a proprietary portfolio of next-generation selective HDAC6 inhibitors for neuromuscular, neurodegenerative, and cardio-metabolic diseases with high unmet need. The company is currently advancing lead candidate AGT-100216 in Phase I trials for Charcot-Marie-Tooth disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeuven, Belgium
HQ citystring
Leuven
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
HDAC6 inhibitors, small molecule therapeutics, neuromuscular disease drugs, neurodegenerative disease therapeutics, cardiometabolic drug development
Industry3 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / HDAC6 Inhibitor Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical drug development and commercialization
TypeOne Time License
Description

Biopharmaceutical company developing small molecule HDAC6 inhibitors through clinical development toward regulatory approval and commercialization. Revenue will be generated through product sales upon regulatory approval. The company is pre-revenue as a clinical-stage biotech, with no approved products yet.

augustinetx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Augustine Therapeutics discovers and develops a portfolio of small-molecule selective HDAC6 inhibitors for chronic diseases. Its lead clinical asset AGT-100216 is a peripherally-restricted selective HDAC6 inhibitor currently in Phase I trials for Charcot-Marie-Tooth disease, with additional pipeline programs in IND-enabling studies (AGT-100XXX), advanced lead optimization (peripheral 2nd-generation HDAC6i for cardiometabolic indications), and lead optimization (brain-penetrant HDAC6i for ALS and other neurodegenerative diseases). All candidates are based on the company's proprietary non-hydroxamate, non-hydrazide chemotype designed to avoid the specificity and toxicity issues of earlier HDAC6 inhibitor generations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AGT-100216 demonstrated impressive preclinical efficacy in CMT studies, showing ability to halt disease progression, significantly reverse disease phenotype, and rescue axonal integrity in a dose-dependent manner
+3 more records
Product overview1 text field

Augustine Therapeutics is a biotechnology company pioneering a new generation of HDAC6 (Histone DeACetylase 6) inhibitors for the treatment of neuromuscular, neurodegenerative, and cardiometabolic diseases. The company's pipeline includes multiple programs: lead candidate AGT-100216 (Phase I clinical stage for Charcot-Marie-Tooth disease), AGT-100XXX (IND-enabling stage), second-generation peripherally-restricted HDAC6 inhibitors for cardiometabolic diseases (advanced lead optimization), and central acting/brain-penetrant HDAC6 inhibitors for neurodegenerative diseases like ALS (lead optimization). All candidates are based on Augustine's novel non-hydroxamate, non-hydrazide producing chemotype designed to achieve selective HDAC6 inhibition while preserving beneficial non-catalytic functions.

Product and service4 records
1AGT-100216
CategoryClinical-stage small molecule therapeutic (HDAC6 inhibitor)
Description

Peripherally-restricted, selective HDAC6 inhibitor lead candidate in Phase I clinical development for Charcot-Marie-Tooth disease; first selective HDAC6 inhibitor from Augustine's pipeline to enter clinical trials.

2AGT-100XXX
CategoryPreclinical small molecule therapeutic (HDAC6 inhibitor)
Description

Peripherally-restricted, selective HDAC6 inhibitor in IND-enabling studies under evaluation for potential clinical studies in several neuromuscular and cardiometabolic indications.

3Peripheral HDAC6i (2nd Generation)
CategoryPreclinical small molecule therapeutic (HDAC6 inhibitor)
Description

Second-generation peripherally-restricted HDAC6 inhibitor in advanced lead optimization for cardiometabolic diseases, designed using Augustine's non-hydroxamate, non-hydrazide chemotype.

4Central Acting HDAC6i
CategoryPreclinical small molecule therapeutic (HDAC6 inhibitor)
Description

Brain-penetrant HDAC6 inhibitor in lead optimization for neurodegenerative diseases such as ALS, designed using Augustine's non-hydroxamate, non-hydrazide chemotype to cross the blood-brain barrier and act on CNS targets.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Leading European Academic Partners (via VLAIO grant)
Strategic tierCore PartnerTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

VLAIO grant project features collaboration with leading European partners (specific partners not named) to broaden insights into HDAC6 biology across different organs and tissues, guiding future clinical development of Augustine's portfolio of next-generation selective HDAC6i molecules.

augustinetx.com
2US ALS Association
Strategic tierCore PartnerTypeOthersAnnounced on2024-02-27
Description

The US ALS Association awarded a USD 300K Lawrence and Isabel Barnett Drug Development Program grant to support preclinical development of brain-penetrant HDAC6 inhibitors for ALS. The association also provides strategic guidance and patient advocacy support. Augustine collaborates with the VIB-KU Leuven Center for Brain & Disease Research for ALS studies supported by this grant.

augustinetx.com
Strategic tierCore PartnerTypeStrategic or Co-development PartnerAnnounced on2024-02-27
Description

Augustine collaborates with the VIB-KU Leuven Center for Brain & Disease Research on ALS research, using human induced pluripotent stem cells (hiPSCs) and mouse models. The collaboration involves Prof. Ludo Van Den Bosch (founding scientist) and Prof. Philip Van Damme (University Hospital Leuven, LEUCALS). The scientific foundation of Augustine originates from this research center.

4University Hospital Leuven
Strategic tierCore PartnerTypeStrategic or Co-development Partner
Description

Collaboration with Professor Philip Van Damme from the University Hospital in Leuven (Leuven Center for ALS - LEUCALS) for ALS research using in vitro and in vivo models as part of the ALS Association-funded project.

augustinetx.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing therapies for muscle disorders including CMT (EDG-5506 in Phase II) and Duchenne muscular dystrophy. Edgewise is a direct neuromuscular disease peer with overlapping patient populations to Augustine's peripheral programs.

TypeBroad incumbent
Description

Late-stage cardiovascular and neuromuscular specialist with cardiac myosin modulator (omecamtiv mecarbil) in development for heart failure and neuromuscular programs in ALS and SMA. Cytokinetics is a broad incumbent directly comparable to Augustine's dual neuromuscular/cardiometabolic positioning.

3Pharnext
TypeDirect peer
Description

Late-stage French biotech developing PXT-3003, the most advanced therapeutic candidate in clinical development for Charcot-Marie-Tooth disease. Pharnext is the closest direct competitor to Augustine in the CMT indication, although it uses a different mechanism (combination of approved drugs).

TypeBroad incumbent
Description

Major neurodegenerative disease player with established ALS franchise (Qalsody for SOD1-ALS) and ongoing CMT programs. Biogen is a broad incumbent overlapping Augustine's CNS (ALS, AD, PD) and rare neuromuscular disease programs.

TypeBroad incumbent
Description

Established commercial-stage rare disease company with multiple neuromuscular franchises including Duchenne muscular dystrophy (Translarna, Emflaza) and gene therapy programs for CNS disorders. PTC is a broad incumbent in neuromuscular disease that may compete with or partner for Augustine's indications.

TypeEmerging player
Description

Clinical-stage genetic medicines company focused on heart failure and cardiomyopathies with gene therapy and small molecule programs. Tenaya is an emerging player in cardiovascular disease that overlaps with Augustine's HFpEF and atrial fibrillation programs.

TypeBroad incumbent
Description

Large antisense oligonucleotide platform company with multiple approved and clinical-stage programs for neuromuscular and neurodegenerative diseases (e.g., Spinraza for SMA, tofersen for SOD1-ALS). Ionis is a broad incumbent in the antisense/RNA space overlapping Augustine's ALS and CMT indications.

TypeEmerging player
Description

South Korean clinical-stage biotech developing Engensis (VM202), a gene therapy for diabetic peripheral neuropathy and ALS. Helixmith is an emerging peer in the peripheral neuropathy and motor neuron disease space where Augustine operates.

TypeDirect peer
Description

Clinical-stage biotech developing selective HDAC6 inhibitors for Charcot-Marie-Tooth disease and other peripheral neuropathies. Regenacy's lead program (ricolinostat) is the most direct comparator to Augustine's AGT-100216, targeting the same HDAC6 mechanism for CMT.

TypeEmerging player
Description

Early-stage HDAC6-focused biotech acquired by Celgene in 2013 and now operating within Bristol Myers Squibb's pipeline. Acetylon represents historical HDAC6 drug development efforts and a relevant comparator for Augustine's selective HDAC6 inhibitor approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Augustine Therapeutics

Biopharmaceuticals / HDAC6 Inhibitor Therapeuticsaugustinetx.com

Augustine Therapeutics is a clinical-stage Belgian biopharmaceutical company developing a proprietary portfolio of next-generation selective HDAC6 inhibitors for neuromuscular, neurodegenerative, and cardio-metabolic diseases with high unmet need. The company is currently advancing lead candidate AGT-100216 in Phase I trials for Charcot-Marie-Tooth disease.

What Augustine Therapeutics does

Augustine Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 as a spin-off from VIB and KU Leuven, headquartered in Leuven, Belgium with a wholly-owned Copenhagen research subsidiary (Augustine Therapeutics Denmark ApS) established in May 2025. The company develops a portfolio of next-generation selective HDAC6 inhibitors built on a proprietary non-hydroxamate, non-hydrazide producing chemotype designed to overcome the specificity limitations, off-target toxicity, and poor drug-like properties of first-generation hydroxamate- and oxadiazole-based HDAC6 inhibitors. Its pipeline targets three therapeutic verticals with high unmet need: neuromuscular diseases led by AGT-100216 in Phase I clinical trials for Charcot-Marie-Tooth disease (a hereditary neuropathy affecting more than 2.5 million people worldwide with no approved disease-modifying treatments); neurodegenerative diseases via brain-penetrant HDAC6 candidates in lead optimization for ALS and other CNS indications; and cardio-metabolic diseases via a second-generation peripherally-restricted program in advanced lead optimization for conditions including heart failure with preserved ejection fraction and atrial fibrillation.

The company's technology platform is grounded in research from Prof. Ludo Van Den Bosch at the VIB-KU Leuven Center for Brain & Disease Research and includes both peripherally-restricted and brain-penetrant selective HDAC6 chemotypes protected by pending patent filings on thiomethyl carbonyl HDAC6/HDAC1/HDAC3 inhibitors. Augustine has built a senior leadership team with extensive big-pharma and biotech experience across Sanofi, Pfizer, Lundbeck, Genzyme, AbbVie, AstraZeneca, Zealand Pharma, and Arkuda Therapeutics, and has constructed a multi-asset pipeline spanning IND-enabling, lead optimization, and clinical stages.

The business model is a traditional pharmaceutical development and commercialization path: Augustine is pre-revenue with no approved products and no disclosed pricing, plans to commercialize through standard pharmaceutical distribution (prescribing physicians, hospital and specialty pharmacies) upon regulatory approval, and acknowledges potential future partnerships with larger pharmaceutical companies for global commercialization. Current funding is sourced from venture capital (cumulative Series A funding of approximately EUR 94.7M led by Novo Holdings, Jeito Capital, Asabys Partners, and Eli Lilly) plus non-dilutive grants from the US ALS Association and the Flanders Agency for Innovation and Entrepreneurship (VLAIO).

Augustine Therapeutics firmographics

Firmographics
Name
Augustine Therapeutics
Legal name
Augustine Therapeutics NV
Website
https://augustinetx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Augustine Therapeutics is a clinical-stage Belgian biopharmaceutical company developing a proprietary portfolio of next-generation selective HDAC6 inhibitors for neuromuscular, neurodegenerative, and cardio-metabolic diseases with high unmet need. The company is currently advancing lead candidate AGT-100216 in Phase I trials for Charcot-Marie-Tooth disease.
Ownership category
akta.pro rank

Augustine Therapeutics industry classification

Industry
Product category
Biopharmaceuticals / HDAC6 Inhibitor Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)

Keywords

  • HDAC6 inhibitors
  • Small molecule therapeutics
  • Neuromuscular disease drugs
  • Neurodegenerative disease therapeutics
  • Cardiometabolic drug development

Where Augustine Therapeutics is headquartered

Location

Headquarters

HQ city
Leuven
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

Augustine Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical drug development and commercialization: Biopharmaceutical company developing small molecule HDAC6 inhibitors through clinical development toward regulatory approval and commercialization. Revenue will be generated through product sales upon regulatory approval. The company is pre-revenue as a clinical-stage biotech, with no approved products yet.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Augustine Therapeutics product offering

Product offering

Core offering

Augustine Therapeutics discovers and develops a portfolio of small-molecule selective HDAC6 inhibitors for chronic diseases. Its lead clinical asset AGT-100216 is a peripherally-restricted selective HDAC6 inhibitor currently in Phase I trials for Charcot-Marie-Tooth disease, with additional pipeline programs in IND-enabling studies (AGT-100XXX), advanced lead optimization (peripheral 2nd-generation HDAC6i for cardiometabolic indications), and lead optimization (brain-penetrant HDAC6i for ALS and other neurodegenerative diseases). All candidates are based on the company's proprietary non-hydroxamate, non-hydrazide chemotype designed to avoid the specificity and toxicity issues of earlier HDAC6 inhibitor generations.

Product overview

Augustine Therapeutics is a biotechnology company pioneering a new generation of HDAC6 (Histone DeACetylase 6) inhibitors for the treatment of neuromuscular, neurodegenerative, and cardiometabolic diseases. The company's pipeline includes multiple programs: lead candidate AGT-100216 (Phase I clinical stage for Charcot-Marie-Tooth disease), AGT-100XXX (IND-enabling stage), second-generation peripherally-restricted HDAC6 inhibitors for cardiometabolic diseases (advanced lead optimization), and central acting/brain-penetrant HDAC6 inhibitors for neurodegenerative diseases like ALS (lead optimization). All candidates are based on Augustine's novel non-hydroxamate, non-hydrazide producing chemotype designed to achieve selective HDAC6 inhibition while preserving beneficial non-catalytic functions.

Differentiator

Problem solved

Functional benefit

Products and services

  • AGT-100216 Peripherally-restricted, selective HDAC6 inhibitor lead candidate in Phase I clinical development for Charcot-Marie-Tooth disease; first selective HDAC6 inhibitor from Augustine's pipeline to enter clinical trials.
  • AGT-100XXX Peripherally-restricted, selective HDAC6 inhibitor in IND-enabling studies under evaluation for potential clinical studies in several neuromuscular and cardiometabolic indications.
  • Peripheral HDAC6i (2nd Generation) Second-generation peripherally-restricted HDAC6 inhibitor in advanced lead optimization for cardiometabolic diseases, designed using Augustine's non-hydroxamate, non-hydrazide chemotype.
  • Central Acting HDAC6i Brain-penetrant HDAC6 inhibitor in lead optimization for neurodegenerative diseases such as ALS, designed using Augustine's non-hydroxamate, non-hydrazide chemotype to cross the blood-brain barrier and act on CNS targets.

Quantifiable outcome

  • AGT-100216 demonstrated impressive preclinical efficacy in CMT studies, showing ability to halt disease progression, significantly reverse disease phenotype, and rescue axonal integrity in a dose-dependent manner
  • +3 more outcomes

Companies that use Augustine Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Augustine Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Augustine Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core partner.

  • Leading European Academic Partners (via VLAIO grant)core partnerStrategic or Co-development Partner · 12 May 2026VLAIO grant project features collaboration with leading European partners (specific partners not named) to broaden insights into HDAC6 biology across different organs and tissues, guiding future clinical development of Augustine's portfolio of next-generation selective HDAC6i molecules.
  • US ALS Associationcore partnerOthers · 27 February 2024The US ALS Association awarded a USD 300K Lawrence and Isabel Barnett Drug Development Program grant to support preclinical development of brain-penetrant HDAC6 inhibitors for ALS. The association also provides strategic guidance and patient advocacy support. Augustine collaborates with the VIB-KU Leuven Center for Brain & Disease Research for ALS studies supported by this grant.
  • VIB-KU Leuven Center for Brain & Disease Researchcore partnerStrategic or Co-development Partner · 27 February 2024Augustine collaborates with the VIB-KU Leuven Center for Brain & Disease Research on ALS research, using human induced pluripotent stem cells (hiPSCs) and mouse models. The collaboration involves Prof. Ludo Van Den Bosch (founding scientist) and Prof. Philip Van Damme (University Hospital Leuven, LEUCALS). The scientific foundation of Augustine originates from this research center.
  • University Hospital Leuvencore partnerStrategic or Co-development PartnerCollaboration with Professor Philip Van Damme from the University Hospital in Leuven (Leuven Center for ALS - LEUCALS) for ALS research using in vitro and in vivo models as part of the ALS Association-funded project.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Augustine Therapeutics competitors and assessment

Company assessment

Direct peers

  • Edgewise Therapeutics: Clinical-stage biotech developing therapies for muscle disorders including CMT (EDG-5506 in Phase II) and Duchenne muscular dystrophy. Edgewise is a direct neuromuscular disease peer with overlapping patient populations to Augustine's peripheral programs.
  • Pharnext: Late-stage French biotech developing PXT-3003, the most advanced therapeutic candidate in clinical development for Charcot-Marie-Tooth disease. Pharnext is the closest direct competitor to Augustine in the CMT indication, although it uses a different mechanism (combination of approved drugs).
  • Regenacy Pharmaceuticals: Clinical-stage biotech developing selective HDAC6 inhibitors for Charcot-Marie-Tooth disease and other peripheral neuropathies. Regenacy's lead program (ricolinostat) is the most direct comparator to Augustine's AGT-100216, targeting the same HDAC6 mechanism for CMT.

Broad incumbents

  • Cytokinetics: Late-stage cardiovascular and neuromuscular specialist with cardiac myosin modulator (omecamtiv mecarbil) in development for heart failure and neuromuscular programs in ALS and SMA. Cytokinetics is a broad incumbent directly comparable to Augustine's dual neuromuscular/cardiometabolic positioning.
  • Biogen: Major neurodegenerative disease player with established ALS franchise (Qalsody for SOD1-ALS) and ongoing CMT programs. Biogen is a broad incumbent overlapping Augustine's CNS (ALS, AD, PD) and rare neuromuscular disease programs.
  • PTC Therapeutics: Established commercial-stage rare disease company with multiple neuromuscular franchises including Duchenne muscular dystrophy (Translarna, Emflaza) and gene therapy programs for CNS disorders. PTC is a broad incumbent in neuromuscular disease that may compete with or partner for Augustine's indications.
  • Ionis Pharmaceuticals: Large antisense oligonucleotide platform company with multiple approved and clinical-stage programs for neuromuscular and neurodegenerative diseases (e.g., Spinraza for SMA, tofersen for SOD1-ALS). Ionis is a broad incumbent in the antisense/RNA space overlapping Augustine's ALS and CMT indications.

Emerging players

  • Tenaya Therapeutics: Clinical-stage genetic medicines company focused on heart failure and cardiomyopathies with gene therapy and small molecule programs. Tenaya is an emerging player in cardiovascular disease that overlaps with Augustine's HFpEF and atrial fibrillation programs.
  • Helixmith: South Korean clinical-stage biotech developing Engensis (VM202), a gene therapy for diabetic peripheral neuropathy and ALS. Helixmith is an emerging peer in the peripheral neuropathy and motor neuron disease space where Augustine operates.
  • Acetylon Pharmaceuticals: Early-stage HDAC6-focused biotech acquired by Celgene in 2013 and now operating within Bristol Myers Squibb's pipeline. Acetylon represents historical HDAC6 drug development efforts and a relevant comparator for Augustine's selective HDAC6 inhibitor approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Augustine Therapeutics social profiles

Digital presence

Augustine Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Augustine Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Augustine Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Augustine Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Augustine Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Augustine Therapeutics

What does Augustine Therapeutics do?

Augustine Therapeutics discovers and develops a portfolio of small-molecule selective HDAC6 inhibitors for chronic diseases. Its lead clinical asset AGT-100216 is a peripherally-restricted selective HDAC6 inhibitor currently in Phase I trials for Charcot-Marie-Tooth disease, with additional pipeline programs in IND-enabling studies (AGT-100XXX), advanced lead optimization (peripheral 2nd-generation HDAC6i for cardiometabolic indications), and lead optimization (brain-penetrant HDAC6i for ALS and other neurodegenerative diseases). All candidates are based on the company's proprietary non-hydroxamate, non-hydrazide chemotype designed to avoid the specificity and toxicity issues of earlier HDAC6 inhibitor generations.

Is Augustine Therapeutics a public or private company?

Augustine Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Augustine Therapeutics founded?

Augustine Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Augustine Therapeutics based?

Augustine Therapeutics is headquartered in Leuven, Belgium, in the Europe region.

How does Augustine Therapeutics make money?

One revenue line is on record: pharmaceutical drug development and commercialization.

Who are Augustine Therapeutics's main competitors?

Direct peers on record are Edgewise Therapeutics, Pharnext and Regenacy Pharmaceuticals. Broad incumbents are Cytokinetics, Biogen, PTC Therapeutics and Ionis Pharmaceuticals. Emerging players are Tenaya Therapeutics, Helixmith and Acetylon Pharmaceuticals.

Does Augustine Therapeutics have an API?

No public API is recorded for Augustine Therapeutics.

What industry is Augustine Therapeutics in?

Augustine Therapeutics's product category is Biopharmaceuticals / HDAC6 Inhibitor Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAugustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific SessionsAugustine Therapeutics will present a late-breaking poster at the ADA's 2026 Scientific Sessions in New Orleans, June 5-8, 2026. The poster will feature in vivo efficacy results for an HDAC6 inhibitor in a preclinical mouse model of heart failure with preserved ejection fraction. The company's CSO highlighted the need for novel HFpEF therapies.Silicon CanalsBelgium’s 10 biggest funding rounds in H1 2025; 5 are hiringBelgian startups raised $378M across 76 rounds in H1 2025, down from €500M in H1 2024. The ten largest rounds include Augustine Therapeutics' €77.7M Series A and Nobi's €35M Series B, with five companies actively hiring.GlobeNewswireAugustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth diseaseAugustine Therapeutics dosed the first patient in its Phase I trial of AGT-100216, a selective HDAC6 inhibitor for Charcot-Marie-Tooth disease. The randomized, double-blind, placebo-controlled trial evaluates safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics in healthy volunteers. The company raised EUR 78 million in Series A financing in March 2025.GlobeNewswireAugustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth diseaseAugustine Therapeutics dosed the first patient in its Phase I trial of AGT-100216, a selective HDAC6 inhibitor for Charcot-Marie-Tooth disease. The randomized, double-blind, placebo-controlled trial evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The company raised EUR 78 million in Series A financing in March 2025.GlobeNewswireAugustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiaryAugustine Therapeutics appointed Rie Schultz Hansen as Chief Scientific Officer and established a Copenhagen-based subsidiary for cardio-metabolic research. The company will advance its lead HDAC6 inhibitor AGT-100216 into a Phase I/II trial for Charcot-Marie-Tooth disease. The subsidiary aims to expand HDAC6i efforts in cardio-metabolic diseases.GlobeNewswireAugustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBOAugustine Therapeutics appointed Virginie Cartage as CFO and Dr. Andy Hu as CBO. The appointments follow a €78 million Series A financing and aim to support its lead HDAC6 inhibitor AGT-100216 for Charcot-Marie-Tooth disease.GlobeNewswireAugustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of DirectorsAugustine Therapeutics appointed Pascale Witz as chair of its board, effective immediately. She brings over 30 years of life sciences experience, including roles at Sanofi and GE Healthcare. The company raised a €78 million Series A in March 2025.GlobeNewswireAugustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing roundAugustine Therapeutics raised EUR 77.7 million (USD 84.8 million) in an oversubscribed Series A round co-led by Novo Holdings and Jeito Capital. Proceeds will advance its lead candidate AGT-100216 for Charcot-Marie-Tooth disease, with Phase I trials starting imminently. The company also plans to advance other HDAC6 inhibitor programs for neurodegenerative and cardio-metabolic diseases.BioSpaceAugustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing roundAugustine Therapeutics raised EUR 77.7 million (USD 84.8 million) in an oversubscribed Series A round co-led by Novo Holdings and Jeito Capital. Proceeds will advance its lead candidate AGT-100216 for Charcot-Marie-Tooth disease, with Phase I trials starting imminently. The company also plans to expand its HDAC6 inhibitor pipeline for neurodegenerative and cardio-metabolic diseases.WebcapitalriesgoAsabys atrae a Novo y a Jeito a su participada Augustine Therapeutics que cierra la Serie A en €78MAugustine Therapeutics closed a €78M Series A led by Asabys and Novo Holdings, with Jeito Capital joining. The funds will advance its HDAC6 inhibitor AGT-216 into a phase I/II trial for Charcot-Marie-Tooth, expected to start in 2025.